Patent intelligence · US
US 11510904
Methods of treating malignant lymphoproliferative disorders
Methods of treating malignant lymphoproliferative disorders
Patent details — US 11510904
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 29, 2022
- Expiration
- Nov 24, 2042
- Applicant
- ACTUATE THERAPEUTICS INC.
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K31/433, A61K31/52
Quick answer
US 11510904 (Methods of treating malignant lymphoproliferative disorders) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Nov 29, 2022. Expires Nov 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACTUATE THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K31/433, A61K31/52, A61K31/53, A61K31/5377
More from ACTUATE THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12083098
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
granted -
US 11980607
Methods of treating malignant lymphoproliferative disorders
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted
Frequently asked questions
What is US patent 11510904?
US 11510904 (Methods of treating malignant lymphoproliferative disorders) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Nov 29, 2022. Expires Nov 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11510904?
ACTUATE THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11510904 expire?
Our index shows an expiration date of Nov 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.